Development of Folate Receptor−Targeted PET Radiopharmaceuticals for Tumor Imaging—A Bench-to-Bedside Journey
The folate receptor-α (FR-α) is overexpressed in many epithelial cancers, including ovary, uterus, kidneys, breast, lung, colon and prostate carcinomas, but shows limited expression in normal tissues such as kidneys, salivary glands, choroid plexus and placenta. FR-α has therefore emerged as a promi...
Main Authors: | Silvan D. Boss, Simon Mensah Ametamey |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-06-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/6/1508 |
Similar Items
-
FDOPA-(18F): a PET radiopharmaceutical recently registered for diagnostic use in countries of the European Union
by: Yanna-Marina Chevalme, et al.
Published: (2007-09-01) -
Experimental assessment of the application possibility of radiopharmaceutical 68Ga-citrate for Pet-imaging of inflammation
by: Lun'yov A.S., et al.
Published: (2014-12-01) -
Two Novel PET Radiopharmaceuticals for Endothelial Vascular Cell Adhesion Molecule-1 (VCAM-1) Targeting
by: Sara Pastorino, et al.
Published: (2021-07-01) -
Folate receptor targeting of radiolabeled liposomes reduces intratumoral liposome accumulation in human KB carcinoma xenografts
by: Christensen E, et al.
Published: (2018-11-01) -
New <sup>55</sup>Co-labeled Albumin-Binding Folate Derivatives as Potential PET Agents for Folate Receptor Imaging
by: Lauren L. Radford, et al.
Published: (2019-11-01)